Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial
COVID-19 is a fatal, fast-spreading pandemic, and numerous attempts are being made around the world to understand and manage the disease. COVID-19 patients may develop a cytokine-release syndrome, which causes serious respiratory diseases and, in many cases, death. The study examined the feasibility...
Main Authors: | Rania M. Sarhan, Ahmed E. Altyar, Ahmed Essam Abou Warda, Yasmine Mohamed Saied, Haytham Soliman Ghareeb Ibrahim, Mona F. Schaalan, Shaimaa Fathy, Neven Sarhan, Marian S. Boshra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/16/4/631 |
Similar Items
-
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
by: Neven Mohamed Sarhan, et al.
Published: (2023-04-01) -
Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial
by: Neven Sarhan, et al.
Published: (2022-09-01) -
Evaluation of the Effects of Pentoxifylline on Stereological Changes in Frozen Ovarian Tissue of Mice
by: E Kargar Abarghooei, et al.
Published: (2020-06-01) -
Evaluation of Pentoxifylline and Colchicine Administration on Clinical Outcomes of Hospitalized Patients with COVID-19
by: AR Eghbali, et al.
Published: (2023-03-01) -
Parsimonious Effect of Pentoxifylline on Angiogenesis: A Novel Pentoxifylline-Biased Adenosine G Protein-Coupled Receptor Signaling Platform
by: William Khoury, et al.
Published: (2023-04-01)